Results for tag: "Kynamro"

Kynamro is a cardiovascular drug used to treat homozygous familial hypercholesterolemia (HoFH). It is a cholesterol-lowering medication that works by reducing the amount of cholesterol produced by the liver. Kynamro is the first and only approved drug for HoFH in the United States. It is also approved in the European Union, Canada, and Australia. Kynamro is a monoclonal antibody that binds to and inhibits the activity of apolipoprotein B-100 (ApoB-100), a protein involved in the production of low-density lipoprotein (LDL) cholesterol. By blocking ApoB-100, Kynamro reduces the amount of LDL cholesterol produced by the liver, which helps to lower cholesterol levels in the blood. Kynamro is marketed by Sanofi Genzyme, a subsidiary of Sanofi, and is available in the United States, European Union, Canada, and Australia. Other companies in the market include Amgen, Pfizer, and Regeneron Pharmaceuticals. Show Less Read more